The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ACHV | +2.63% | -39.06% | -9.43% | -99% |
| S&P | +13.01% | +86.49% | +13.27% | +176% |
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.05M | 5.3% |
| Market Cap | $160.98M | -1.1% |
| Market Cap / Employee | $6.44M | 0.0% |
| Employees | 25 | 13.6% |
| Net Income | -$14.44M | -15.4% |
| EBITDA | -$14.64M | -18.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $31.93M | 234.6% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $8.70M | -11.5% |
| Short Term Debt | $1.26M | 5640.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -104.74% | -13.6% |
| Return On Invested Capital | 263.18% | -7.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$11.33M | -9.2% |
| Operating Free Cash Flow | -$11.33M | -9.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.86 | 4.43 | 7.63 | 3.76 | -27.70% |
| Price to Tangible Book Value | 4.13 | 4.90 | 9.41 | 3.94 | -29.23% |
| Enterprise Value to EBITDA | -8.00 | -6.18 | -2.63 | -8.37 | -19.95% |
| Return on Equity | -409.5% | -154.5% | -120.1% | -161.1% | -13.41% |
| Total Debt | $9.96M | $9.96M | $9.96M | $9.96M | 1.15% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
